Cargando…

Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis

Background: The incidence of Non-alcoholic fatty liver disease (NAFLD) is increasing year by year. Researches showed that Chinese patent medicines (CPMs) had achieved good efficacy in the treatment of Non-alcoholic fatty liver disease. However, the debate on optimum Chinese patent medicine (CPM) per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lihui, Liu, Sutong, Gu, Yajiao, Li, Shanzheng, Liu, Minghao, Zhao, Wenxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847677/ https://www.ncbi.nlm.nih.gov/pubmed/36686656 http://dx.doi.org/10.3389/fphar.2022.1077180

Ejemplares similares

Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine
por: Shao, Mingmei, et al.
Publicado: (2022)

Efficacy and Safety of Chinese Patent Medicine Combined With Oseltamivir in Treatment of Children With Influenza: A meta-Analysis
por: Duan, Nai-fan, et al.
Publicado: (2021)

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application
por: Xu, Yu, et al.
Publicado: (2020)

An Efficacy and Feasibility Analysis of Chinese Patent Medicine Combined With Letrozole in the Treatment of Women With Ovulation Disorders: A Network Meta-Analysis
por: Zhu, Jing-Yan, et al.
Publicado: (2021)

The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
por: Huang, Peiying, et al.
Publicado: (2022)

Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment
por: Liu, Tingting, et al.
Publicado: (2022)

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
por: Zhuang, Wei, et al.
Publicado: (2020)

Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review
por: Yang, Zhi-Hua, et al.
Publicado: (2021)

A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China
por: Zhang, Nan, et al.
Publicado: (2020)

Lipophagy and Alcohol-Induced Fatty Liver
por: Yang, Li, et al.
Publicado: (2019)

Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis
por: Liu, Jiarong, et al.
Publicado: (2022)

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines
por: Wu, Ying, et al.
Publicado: (2021)

Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review
por: Yang, Zhi-Hua, et al.
Publicado: (2021)

Comparative Efficacy of Oral Chinese Patent Medicine for Chronic Prostatitis/Chronic Pelvic Pain Syndrome With Sexual Dysfunction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
por: Zhang, Yang, et al.
Publicado: (2021)

Efficacy and Safety of Chinese Patent Medicine for the Prevention and Treatment of Radiotherapy and Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis
por: Xie, Yufei, et al.
Publicado: (2022)

Platelets in Non-alcoholic Fatty Liver Disease
por: Dalbeni, Andrea, et al.
Publicado: (2022)

Observation of Voriconazole in the Treatment of Liver Failure Complicated With Invasive Pulmonary Fungal Infection Induced by Chinese Patent Medicine in Teenagers: 2 Case Reports
por: Su, Qian, et al.
Publicado: (2022)

LncRNA-AK012226 Is Involved in Fat Accumulation in db/db Mice Fatty Liver and Non-alcoholic Fatty Liver Disease Cell Model
por: Chen, Xingtian, et al.
Publicado: (2018)

Comparative clinical-related outcomes of Chinese patent medicines for cardiac hypertrophy: A systematic review and network meta-analysis of randomized clinical trials
por: Zhang, Tianqi, et al.
Publicado: (2023)

Aurantio-Obtusin Attenuates Non-Alcoholic Fatty Liver Disease Through AMPK-Mediated Autophagy and Fatty Acid Oxidation Pathways
por: Zhou, Fei, et al.
Publicado: (2022)

Quantitative Determination and Toxicity Evaluation of Aristolochic Acid Analogues in Asarum heterotropoides F. Schmidt (Xixin) and Traditional Chinese Patent Medicines
por: Liu, Suyan, et al.
Publicado: (2021)

Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Peng, Sihan, et al.
Publicado: (2022)

Erratum: A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China
por: Frontiers Production Office,
Publicado: (2021)

Analysis of the correlation between non-alcoholic fatty liver disease and the risk of colorectal neoplasms
por: Ye, Shujun, et al.
Publicado: (2022)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Yu, Siyu, et al.
Publicado: (2021)

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
por: Fu, Yajie, et al.
Publicado: (2022)

Alcohol in Patent Medicines
Publicado: (1891)

Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
por: Li, Zhen, et al.
Publicado: (2023)

A specific SNP-based multiplex PCR assay for the simultaneous identification of two biological ingredients for the Chinese patent medicine, Danggui Buxue pill
por: Liu, Yinrong, et al.
Publicado: (2023)

TaqMan Probe-Based Quantitative Real-Time PCR to Detect Panax notoginseng in Traditional Chinese Patent Medicines
por: Lou, Qian, et al.
Publicado: (2022)

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis
por: Jiang, Li, et al.
Publicado: (2022)

The protective roles of augmenter of liver regeneration in hepatocytes in the non-alcoholic fatty liver disease
por: Dong, Yuan, et al.
Publicado: (2022)

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
por: Chandrasekharan, Karthik, et al.
Publicado: (2020)

Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhang, Xiao-Wen, et al.
Publicado: (2022)

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

The Species Identification in Traditional Herbal Patent Medicine, Wuhu San, Based on Shotgun Metabarcoding
por: Liu, Jinxin, et al.
Publicado: (2021)

Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease
por: Xu, Jingqi, et al.
Publicado: (2021)

Therapeutic potential of traditional Chinese medicine on heat stroke
por: Li, Lei, et al.
Publicado: (2023)

A Traditional Chinese Medicine Plant Extract Prevents Alcohol-Induced Osteopenia
por: Qian, Dongyang, et al.
Publicado: (2021)

Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms
por: Cui, Yizhe, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_300die0ehn0biic1eu2v0fh1v7